Tryptamine Therapeutics (ASX:TYP) COGS-to-Revenue : 0.00 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Tryptamine Therapeutics COGS-to-Revenue?

Tryptamine Therapeutics's Cost of Goods Sold for the six months ended in Dec. 2023 was A$0.00 Mil. Its Revenue for the six months ended in Dec. 2023 was A$0.00 Mil.

Tryptamine Therapeutics's COGS to Revenue for the six months ended in Dec. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Tryptamine Therapeutics's Gross Margin % for the six months ended in Dec. 2023 was N/A%.

Tryptamine Therapeutics COGS-to-Revenue Historical Data

The historical data trend for Tryptamine Therapeutics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tryptamine Therapeutics COGS-to-Revenue Chart

Tryptamine Therapeutics Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

COGS-to-Revenue

Get a 7-Day Free Trial

Tryptamine Therapeutics Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial						-	-	-	-	-

Tryptamine Therapeutics COGS-to-Revenue Calculation

Tryptamine Therapeutics's COGS to Revenue for the fiscal year that ended in Jun. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0.619
	=	0.00

Tryptamine Therapeutics's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Tryptamine Therapeutics (ASX:TYP) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Tryptamine Therapeutics's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Tryptamine Therapeutics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Tryptamine Therapeutics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Tryptamine Therapeutics (ASX:TYP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (ASX:TYP) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

697 Burke Road, Suite 201, Camberwell, VIC, AUS, 3124

Website

https://www.exopharm.com

Exopharm Ltd is a biopharmaceutical company that engages in the development of regenerative medicine in Australia. The company is engaged in developing and commercializing exosomes as therapeutic agents. The company operates in one segment namely the research and development of biopharmaceutical drugs. Revenue is generated from Australia.

Tryptamine Therapeutics (ASX:TYP) Headlines

No Headlines